Evidence map›Paper›PMID 26926996›Full record

ArticleThe Journal of experimental medicine2016

The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease.

Tsuyoshi Shirai, Rafal R Nazarewicz, Barbara B Wallis, Rolando E Yanes, Ryu Watanabe, Marc Hilhorst, Lu Tian, David G Harrison, John C Giacomini, Themistocles L Assimes and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 336 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
336citing papers in PubMed, 1 pooled it
22.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

336 citing papers in PubMed, 1 synthesis or guideline pooled it, 531 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Na/K-ATPase Signaling in Adipocytes Promotes Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  9. PKM2: A gatekeeper in macrophage metabolic reprogramming.Journal of pharmaceutical analysis · 2026
    Review
  10. Review
  11. Article
  12. Review
  13. Glycolytic reprogramming in host response toExperimental and therapeutic medicine · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Qianyang Yuyin granule modulates glycolysis and inflammatory response to treat hypertensive cardiac remodeling.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2026
    Article
  18. Article
  19. Article
  20. Article

276 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Tsuyoshi ShiraiDivision of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Rafal R NazarewiczDivision of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232.
Barbara B WallisDivision of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Rolando E YanesDivision of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Ryu WatanabeDivision of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Marc HilhorstDivision of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Lu TianDivision of Biostatistics, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305.
David G HarrisonDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232.
John C GiacominiDivision of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Themistocles L AssimesDivision of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Jörg J GoronzyDivision of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Cornelia M WeyandDivision of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 cweyand@stanford.edu.
Stanford University · USVanderbilt University · US

Funding

Vascular specific ACE expression and atherosclerosisP01HL058000 · NHLBI · VANDERBILT UNIVERSITY · PI HARRISON, DAVID G · 1998 to 2013
$20.7M
The NOTCH Signaling Pathway in Large Vessel VasculitisR01HL117913 · NHLBI · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 2014 to 2025
$5.0M
Oligoclonal T Cell Expansion &Rheumatoid ArthritisR01AR042527 · NIAMS · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 1993 to 2022
$4.8M
microRNA Regulation of T Cell SenescenceR01AI108891 · NIAID · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI GORONZY, JORG J · 2014 to 2023
$4.6M
Telomere Damage Responses and Immune AgingR01AI108906 · NIAID · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 2014 to 2024
$4.0M
Influence of Age on CD4 T Memory CellsR01AG045779 · NIA · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI GORONZY, JORG J · 2013 to 2023
$4.0M
CD8 T CELLS IN RHEUMATOID SYNOVITISR01AI044142 · NIAID · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 1999 to 2010
$2.9M
CD8 T cells in Rheumatoid ArthritisR56AI044142 · NIAID · STANFORD UNIVERSITY · PI WEYAND, CORNELIA M. · 2013 to 2013
$369k
FAS ANTIGEN AND LIGAND--FUNCTIONAL CHARACTERIZATIONR01AR042547 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOUNTZ, JOHN D · 1993 to 1997
–
NHLBI NIH HHS HL058000NHLBI NIH HHS HL117913NHLBI NIH HHS P01 HL058000NHLBI NIH HHS R01 HL117913NIAID NIH HHS AI044142NIAID NIH HHS AI108891NIAID NIH HHS R01 AI044142NIAID NIH HHS R01 AI108891NIAID NIH HHS R01 AI108906NIAID NIH HHS R56 AI044142NIAMS NIH HHS AR042547NIAMS NIH HHS R01 AR042527NIA NIH HHS AG045779NIA NIH HHS R01 AG045779
6 · The paper itself

Abstract

Abnormal glucose metabolism and enhanced oxidative stress accelerate cardiovascular disease, a chronic inflammatory condition causing high morbidity and mortality. Here, we report that in monocytes and macrophages of patients with atherosclerotic coronary artery disease (CAD), overutilization of glucose promotes excessive and prolonged production of the cytokines IL-6 and IL-1β, driving systemic and tissue inflammation. In patient-derived monocytes and macrophages, increased glucose uptake and glycolytic flux fuel the generation of mitochondrial reactive oxygen species, which in turn promote dimerization of the glycolytic enzyme pyruvate kinase M2 (PKM2) and enable its nuclear translocation. Nuclear PKM2 functions as a protein kinase that phosphorylates the transcription factor STAT3, thus boosting IL-6 and IL-1β production. Reducing glycolysis, scavenging superoxide and enforcing PKM2 tetramerization correct the proinflammatory phenotype of CAD macrophages. In essence, PKM2 serves a previously unidentified role as a molecular integrator of metabolic dysfunction, oxidative stress and tissue inflammation and represents a novel therapeutic target in cardiovascular disease.

Indexed as

GlycolysisAgedCell RespirationCoronary Artery DiseaseFemaleGlucoseHumansInflammationInterleukin-1betaInterleukin-6MacrophagesMaleMitochondriaMonocytesPhenotypePhosphorylationGlucoseInterleukin-1betaInterleukin-6Pyruvate KinaseReactive Oxygen SpeciesSTAT3 Transcription Factor

Identifiers

PMID26926996
PMCPMC4813677
OpenAlexW2296002833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.